Inserm U1019, CNRS UMR8204, Center for Infection & Immunity of Lille, Institut Pasteur de Lille, Université Lille Nord de France, Lille, France.
Viruses. 2012 Oct 17;4(10):2197-217. doi: 10.3390/v4102197.
Hepatitis C is a major global health burden with an estimated 160 million infected individuals worldwide. This long-term disease evolves slowly, often leading to chronicity and potentially to liver failure. There is no anti-HCV vaccine, and, until recently, the only treatment available, based on pegylated interferon and ribavirin, was partially effective, and had considerable side effects. With recent advances in the understanding of the HCV life cycle, the development of promising direct acting antivirals (DAAs) has been achieved. Their use in combination with the current treatment has led to encouraging results for HCV genotype 1 patients. However, this therapy is quite expensive and will probably not be accessible for all patients worldwide. For this reason, constant efforts are being made to identify new antiviral molecules. Recent reports about natural compounds highlight their antiviral activity against HCV. Here, we aim to review the natural molecules that interfere with the HCV life cycle and discuss their potential use in HCV therapy.
丙型肝炎是全球重大健康负担之一,全球估计有 1.6 亿感染者。这种慢性疾病发展缓慢,常导致慢性化,并可能导致肝功能衰竭。目前尚无抗 HCV 疫苗,直到最近,唯一可用的治疗方法是基于聚乙二醇干扰素和利巴韦林的治疗方法,部分有效,但副作用较大。随着对 HCV 生命周期理解的最新进展,有希望的直接作用抗病毒药物 (DAA) 的开发已经取得进展。它们与现有治疗方法联合使用,为 HCV 基因型 1 患者带来了令人鼓舞的结果。然而,这种治疗方法非常昂贵,可能无法在全球范围内为所有患者提供。出于这个原因,人们正在不断努力寻找新的抗病毒分子。最近关于天然化合物的报告强调了它们对 HCV 的抗病毒活性。在这里,我们旨在综述干扰 HCV 生命周期的天然分子,并讨论它们在 HCV 治疗中的潜在用途。